JP7863050B2 - ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療 - Google Patents

ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療

Info

Publication number
JP7863050B2
JP7863050B2 JP2022569509A JP2022569509A JP7863050B2 JP 7863050 B2 JP7863050 B2 JP 7863050B2 JP 2022569509 A JP2022569509 A JP 2022569509A JP 2022569509 A JP2022569509 A JP 2022569509A JP 7863050 B2 JP7863050 B2 JP 7863050B2
Authority
JP
Japan
Prior art keywords
riz2
sirna
inhibitor
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022569509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526328A5 (enExample
JP2023526328A (ja
Inventor
ブックバインダー，ロニー・エル
ベイッシュ，ナレンドラ・ケイ
ナイルズ，ブラッド・ジェイ
フリン，ジョナサン
ヌニェス，ニコル
Original Assignee
エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド filed Critical エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド
Publication of JP2023526328A publication Critical patent/JP2023526328A/ja
Publication of JP2023526328A5 publication Critical patent/JP2023526328A5/ja
Application granted granted Critical
Publication of JP7863050B2 publication Critical patent/JP7863050B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022569509A 2020-05-14 2021-05-13 ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療 Active JP7863050B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024624P 2020-05-14 2020-05-14
US63/024,624 2020-05-14
PCT/US2021/032311 WO2021231771A2 (en) 2020-05-14 2021-05-13 CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN

Publications (3)

Publication Number Publication Date
JP2023526328A JP2023526328A (ja) 2023-06-21
JP2023526328A5 JP2023526328A5 (enExample) 2024-05-17
JP7863050B2 true JP7863050B2 (ja) 2026-05-20

Family

ID=78525067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569509A Active JP7863050B2 (ja) 2020-05-14 2021-05-13 ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療

Country Status (5)

Country Link
US (2) US12012597B2 (enExample)
EP (1) EP4150093A4 (enExample)
JP (1) JP7863050B2 (enExample)
CN (1) CN116113421A (enExample)
WO (1) WO2021231771A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7863050B2 (ja) 2020-05-14 2026-05-20 エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療
US20260224735A1 (en) * 2023-01-10 2026-08-06 Ariz Precision Medicine, Inc. Targeted anti-prdm compositions and uses thereof
CN119405814A (zh) * 2024-12-18 2025-02-11 青岛大学附属医院 Eno1作为靶点在制备治疗膀胱癌的药物组合物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503131A (ja) 2001-05-11 2005-02-03 ザ バーナム インスティチュート Ｒｉｚに関するスクリーニング、診断および治療の方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831008A (en) * 1994-08-18 1998-11-03 La Jolla Cancer Research Foundation Retinoblastoma protein-interacting zinc finger proteins
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7439208B2 (en) 2003-12-01 2008-10-21 Superconductor Technologies, Inc. Growth of in-situ thin films by reactive evaporation
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2005111238A2 (en) * 2004-04-19 2005-11-24 Archemix Corporation Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
JP4352976B2 (ja) 2004-04-20 2009-10-28 株式会社日立製作所 受信装置及び受信方法
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
AU2005250464B2 (en) 2004-06-01 2010-10-07 The Penn State Research Foundation Unagglomerated core/shell nanocomposite particles
US8603991B2 (en) * 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
WO2008038832A1 (en) 2006-09-27 2008-04-03 Sapporo Medical University Therapeutic agent, detection method and detection kit for breast cancer and ovarian cancer
US8771741B2 (en) 2009-01-23 2014-07-08 The Penn State Research Foundation In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
WO2011050178A2 (en) 2009-10-21 2011-04-28 Lonnie Bookbinder Targeted prdm gene or protein modulation therapeutic agents
US9149544B2 (en) 2009-11-06 2015-10-06 The Penn State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
JP6033218B2 (ja) 2010-05-21 2016-11-30 ペプティメド， インコーポレイテッド がんを治療するための試薬および方法
SG10201508981YA (en) 2010-11-01 2015-11-27 Peptimed Inc Compositions Of A Peptide-Based System For Cell-Specific Targeting
US10226424B2 (en) 2012-08-12 2019-03-12 Mylisa Parette Therapeutic calcium phosphate nanoparticle incorporating siRNA useful in treating disease
JP6683986B2 (ja) 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
CA2921005A1 (en) * 2013-08-16 2015-02-19 Ohio State Innovation Foundation Compositions and methods for modulating dna methylation
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
SG10201806064XA (en) 2014-08-27 2018-08-30 Peptimed Inc Anti-tumor compositions and methods
WO2016065273A1 (en) 2014-10-24 2016-04-28 The University Of Chicago Heat-inducible self-assembling protein domains
EP3359167A4 (en) * 2015-10-09 2019-11-13 Children's Medical Center Corporation METHOD AND COMPOSITIONS FOR INCREASING HUMAN SOMATIC CELL CORE TRANSFER EFFICIENCY BY REMOVING HISTON-H3-LYSINE TRIMETHYLATION AND DERIVING FROM HUMAN NT-ESC
JP2022545055A (ja) 2019-07-09 2022-10-25 アライズ プレシジョン メディシン，インク． ＰＲＤＭ１４タンパク質の発現をダウンレギュレートする標的化ｓｉＲＮＡ製剤を使用する癌処置
JP7863050B2 (ja) 2020-05-14 2026-05-20 エイアールアイズィー・プリシジョン・メディスン・インコーポレイテッド ｓｉＲＮＡを使用してＰＲＤＭ２／ＲＩＺタンパク質の発現を調節するがん治療

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503131A (ja) 2001-05-11 2005-02-03 ザ バーナム インスティチュート Ｒｉｚに関するスクリーニング、診断および治療の方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Experimental Cell Research，2006年，Vol.312，pp.340-349
Nucleic Acids Research，2015年，Vol.43, No.13，pp.6236-6256
Open Life Sci，2016年，Vol.11，pp.136-141

Also Published As

Publication number Publication date
EP4150093A4 (en) 2024-06-19
WO2021231771A2 (en) 2021-11-18
JP2023526328A (ja) 2023-06-21
WO2021231771A3 (en) 2021-12-30
US20230099879A1 (en) 2023-03-30
CN116113421A (zh) 2023-05-12
US12012597B2 (en) 2024-06-18
EP4150093A2 (en) 2023-03-22
US20240360445A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
TWI886314B (zh) 抑制ｌｐａ表現之組合物及方法
AU2015252917B2 (en) Compositions and methods for modulating PKK expression
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
EP2751128B1 (en) Cell-penetrating peptides having a central hydrophobic domain
EP2419144B1 (en) Composition for delivery of genetic material
JP2022525208A (ja) 組織特異的なａｐｏｅ調節のためのオリゴヌクレオチド
JP2022528487A (ja) Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節
KR20210005031A (ko) Pten 억제제를 포함하는 소포 및 이의 용도
US20240360445A1 (en) CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN
US20160348113A1 (en) Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use
CN1703229B (zh) 治疗前列腺和其他癌的组合物和其制备药物的用途
JP7382919B2 (ja) トランスフェリン受容体（ＴｆＲ）に対するＲＮＡアプタマー
JP2018531046A (ja) 核酸ベースのｔｉａ−１阻害剤
US20230151369A1 (en) Compositions and methods for inhibiting tdp-43 and fus aggregation
US11981896B2 (en) p21 mRNA target areas for silencing
WO2018221649A1 (ja) Ａｐｃｓの発現を抑制する核酸
CN103370414A (zh) 降低恶性神经胶质瘤中下调肾细胞癌的表达的方法
CN101821410B (zh) 印迹位点调节物兄弟(boris)的基因沉默
RU2800729C2 (ru) Везикулы, содержащие ингибитор pten, и их применение
Wang Poly (ethylene) Glycol-Based Bottlebrush Polymers as Nanocarriers for Oligonucleotide Therapeutics: Design, Synthesis, and Applications
HK40127600A (en) Compositions and methods for inhibiting adenylate cyclase 9 (ac9)
TW202345873A (zh) 調節ｓｃａｐ活性之組合物及方法
HK1194389A (en) Cell-penetrating peptides having a central hydrophobic domain
HK1194389B (en) Cell-penetrating peptides having a central hydrophobic domain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260508

R150 Certificate of patent or registration of utility model

Ref document number: 7863050

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150